Abstract Cancer stem cells (CSCs) need to survive cancer treatments with a specific end goal to provide new, more differentiated, metastatic-prone cancerous cells. This happens through diverse signals delivered within the tumor microenvironment where ample evidence indicates that altered developmental signaling pathways play an essential role in maintaining CSCs and accordingly the survival and the progression of the tumor itself. This review summarizes findings on the immunobiological properties of CSCs as compared with cancerous non-stem cells involving the expression of immunological molecules, cytokines and tumor antigens as well as the roles of the Notch, Wnt and Hedgehog pathways in the brain, breast and colon CSCs. We concluded that if CSCs are the main driving force behind tumor support and growth then understanding the molecular mechanisms and the immunological properties directing these cells for immune tolerance is of great clinical significance. Such knowledge will contribute to designing better targeted therapies that could prevent tumor recurrence and accordingly significantly improve cancer treatments and patient survival.
Introduction
Cancer stem cells (CSCs) can be defined as a rare subpopulation of cancer cells which have the properties of self-renewal, differentiation, multipotency, cancer initiation and resistance to chemotherapy and radiotherapy (Clevers 2011) . CSCs have the capability of being resistant to chemotherapy and radiotherapy by many molecular mechanisms. For example, it has been established that increases in the aldehyde dehydrogenase (ALDH) activity in CSC seem to mediate their resistance to particular chemotherapeutics (Hilton 1984; Ginestier et al. 2007 ). Additionally, CSCs chemo/radiotherapy resistance is depicted to be reliant on interleukin-4 (IL-4) signaling pathway since upregulation of IL-4 on these cells results in resistance to apoptosis (Francipane et al. 2008 ). As such, acquisition of these properties by CSCs make them refractory to immunotherapy (Ellebaek et al. 2012 ). In addition, CSCs display an epithelial-mesenchymal cell transition (EMT) which is another mechanism that supports their resistance to chemotherapy and other therapeutic drugs (Kalluri and Weinberg 2009) . Another mechanism of chemo resistance that has been overall investigated in CSCs is the role of B-cell lymphoma-2 (BCL-2) protein and its family members (Kelly and Strasser 2011) . Taken together, CSCs are equipped with different mechanisms that render them insensitive to chemotherapy, radiotherapy and immunotherapy.
A paramount and fascinating common theme has been the finding that differentially expressed markers on the normal stem cells of the tissue in which a cancer has emerged are often useful for the identification and isolation of the CSCs. However, the exact molecular characterization of CSCs is still unclear because a variety of putative CSC-associated markers have been distinguished up to this point in solid tumors (Table 1) where none of them have been reported to be only expressed by the CSCs (Li and Laterra 2012; Magee et al. 2012 ). Absence of a single CSC-specific marker can explain the inter-patients contrasts of the genetic background and intra-and/or inter-cancer heterogeneity of the original tumor (Hjelmeland and Rich 2012; Li and Laterra 2012) . Examples of common CSC markers are listed in Table 1 .
Immunological features of CSCs
The expression of both antigen presentation and costimulatory molecules by a given cell, including cancer cells, is a prerequisite for them to act as professional antigen presenting cells. As such, the expression pattern of the antigen presentation molecules, including major histocompatibility complex (MHC) class-I (MHC-I) and class-II (MHC-II) molecules as well as the co-stimulatory and co-inhibitory molecules by CSCs determines their immunological signature and if they can present tumor antigens to T cells for immune recognition or eliciting productive immune responses (Comber and Philip 2014) .
Indeed, CSCs show down-regulation of MHC-I and a lack of MHC-II expression (Hjelmeland and Rich 2012) . Of note, normal hematopoietic stem cells has low MHC-I expression as well (Le Blanc et al. 2003) which suggests that the low expression of MHC-I in both cell types supports the stem cell survival through escaping from the immune attack. As a consequence for the low expression of MHC-I, the antigen processing system is down-regulated in CSCs, especially the low molecular weight protein (LMPs), transporter associated with antigen processing (TAP) and beta macroglobulin have been shown to be downregulated in the CSCs (Di Tomaso et al. 2010) .
Considering the expression of the co-stimulatory molecules (CD80, CD86) and the co-inhibitory molecules (CTLA4, B7-H2, B7-H3 and PD-1/-1L) in CSCs, it has been found that these cells are negative for the co-stimulatory molecules where the co-inhibitory molecules were up-regulated in comparison with the conventional cancer cells (Maccalli et al. 2013 ). Based on this unique phenotype of CSC it could be suggested that the antigen presentation of these cells is dysfunctional.
With respect to the cytokines released by cancerous cells, transforming growth factor (TGF)-b1, TGF-b2, tumor necrosis factor (TNF), IL-8, IL-10, IL-6 and IL-13 were found to be released from different cancer cells of different histology. CSCs have been shown to secrete TGF-b, IL-10, IL-13 in vitro (Schatton and Frank 2009 
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? Schatton et al. (2008) detailed analysis of the soluble factors including cytokines and growth factors expressed by CSCs from glioblastoma in vitro. They found that CSCs showed a high release of tumor associated angiogenic factors such as vascular endothelial growth factor (VEGF), macrophage-chemoattractant protein-1 (MCP-1), eotaxin, macrophage inhibitory factor (MIF) and growth related oncogene a (GROa) (Di Tomaso et al. 2010) . Surprisingly, IL-10 or IL-13 were not released by CSCs (Di Tomaso et al. 2010) , indicating that CSCs may depend mainly on their angiogenic factors as an intrinsic mechanism to sustain their survival and trafficking.
Tumor associated antigens expressed by CSCs
Expression of tumor associated antigens (TAAs) by cancerous cells is another important factor that determines the immunogenic nature of cancer cells (Lucas and Coulie 2008) . Interestingly, CSCs express a variety of molecules that describe their stemness condition and could be conceivably distinguished by the immune system as TAAs (Parmiani et al. 2007 ). In melanoma for instance, the CSC subpopulation expressing the ABCB5 molecule, which is expressed in human malignant melanoma and supports tumor cell dispersal through mediating chemotherapeutic drug resistance, showed a low level of lineage-related and cancer-testis (CT) antigens (Schatton et al. 2010 ). The CD133 ? subpopulation of melanoma cells, however, had high expression of NY-ESO1 CT antigen along with susceptibility to specific T cells (Gedye et al. 2009 ).
Recently, a new TAA has been characterized in CD133
? CSCs in murine melanoma and in many human cancers (called DDX3X), conferring to the immunogenicity of these cells and their capability to induce a T-cell dependent protection against murine cancer growth in vivo (Koshio et al. 2013) . In contrast, another subpopulation (CD271 ? ) of melanoma CSCs are deficient in the expression of both lineage related and CT antigens, making their removal by the immune T cells rather difficult (Boiko et al. 2010 ) which correlated with the progression and metastasis of these cells. As such, melanoma cells offer an example of multiple CSC subpopulations with different antigen expression patterns. Of note, none of these potential TAAs represents a specific marker of CSCs because they are often expressed by non-stem cancer cells. Nonetheless, they can be considered as potential useful targets to direct immune response against melanoma and CSC melanoma simultaneously.
The functional in vitro and in vivo immunogenicity of CSCs has been deliberated in a limited number of cases. Interestingly, a new group of molecules, the heat-shock proteins (HSP), commonly expressed in many murine and human tumors and to be immunogenic in vivo and in vitro (Parmiani et al. 2007) , have been demonstrated to preserve CSCs or at least for a subfamily of them (HSP40). These HSPs demonstrated high expression in most human solid tumors including renal cell carcinoma (RCC), and prompted cytotoxic T lymphocytes (CTL) reactions in vitro favored with a therapeutic potential at least in the mouse system (Nishizawa et al. 2012) . It has been indicated, however, that other lymphocyte subpopulations (e.g. natural killer (NK) cells or cd-T lymphocytes) may distinguish and kill in vitro human CSCs isolated from gliomas, CRC, ovarian cancers and melanoma (Avril et al. 2011; Lai et al. 2012) .
Indeed, the relative immunogenicity of CSCs makes them a potential target for vaccination based cancer immunotherapy. With this regard, in a recent study of vaccination of mice with dendritic cells pulsed with syngeneic CSC lysate as TAAs, an effective therapeutic and immunological (both antibody and T cell-mediated) reaction has been acquired (Ning et al. 2012) . Further, given that characterization of CSCs depends on their expression of ALDH, it is possible to generate anti-ALDH-specific CTLs with a therapeutic activity against human CSCs when xenografted into severe combined immunodeficiency (SCID) mice (Visus et al. 2011 ). These studies indicate the possible utility of CSCs in anti-cancer vaccination. Since tumors share expression of embryonic gene products (Brewer et al. 2009) , it is possible to vaccinate with undifferentiated ESCs to generate anti-tumor immunity. Indeed, vaccination with ESCs was demonstrated to trigger anti-tumor immunity against transplantable colon carcinoma and lung cancer (Li et al. 2009a, b; Dong et al. 2010 Dong et al. , 2013 and prevented implantable and carcinogen-induced lung tumors, coinciding with robust anti-tumor-specific effector and memory CD8
? T responses, Th1 cytokine response, lower numbers of immunosuppressive cells including regulatory T cells and myeloid derived suppressor cells (Yaddanapudi et al. 2012) . Cytotechnology (2015) 
Notch pathway
The Notch signaling pathway is evolutionarily conserved and plays numerous roles. For example, it impacts stem cell fate, differentiation and cell cycle progression. Notch signaling might be either inhibitory or inductive depending on the context (Purow et al. 2005) . Mammals have four Notch receptors (Notch1, Notch2, Notch3, and Notch4) and five ligands including the delta-like proteins (DLL1, DLL3, and DLL4) and Jagged proteins (JAG1 and JAG2). The Notch receptors are transmembrane proteins with an extracellular domain with EGF-like repeats included in the ligand binding and an intracellular domain (ICD) (Blank et al. 2008) . In brain cancers, components of the Notch signaling pathway are up-regulated and several studies have Notch1 and its ligands DLL1 and JAG1 are over-expressed in primary gliomas (Purow et al. 2005) , downregulation of Notch signaling components expanded apoptosis and diminished cell proliferation (Purow et al. 2005) , down-regulation of Notch components sensitized CSCs to radiation or chemotherapeutic therapies and weakened xenograft tumor formation Expression of Notch signaling components is common in human breast cancers, where up to 50 % of the cells showed Notch activation (Pece et al. 2004 ) and high JAG1 and NOTCH1 expression is connected with poor survival (Reedijk et al. 2005) Notch signals are high in early colorectal cancers (Reedijk et al. 2008 ) and appear to be lower in advanced cancers (Fre et al. 2005) and Notch is essential for selfrenewal and tumor initiation (Fre et al. 2005) Wnt signaling Down-regulation of the secreted Frizzled-related proteins (SFRPs), which are Wnt inhibitors, has been observed in breast cancers (Veeck et al. 2008) , Wnt/b-catenin signaling participates in the radiation therapy resistance of breast CSCs (55) Mutations in APC, b-catenin, and Axin have been found in medulloblastomas (Baeza et al. 2003) , the Wnt antagonist DKK-1 has been ensnared as a medulloblastoma suppressor (59) Inactivating mutations in APC are found in up to 80 % of sporadic colon cancers and activating mutations of b-catenin are additionally discovered, both of which culminate in actuated Wnt signaling (Pinto et al. 2003) Hedgehog signaling
Brain cancers have inactivating PTCH1 mutations (Hahn et al. 1996) , GLI1 was highly expressed in 26 % of primary GBMs and 57 % of cell lines (Bar et al. 2007 ) and GLI1 shRNA brought about a critical diminishing in glioma development in vitro (Bao et al. 2006) Breast cancers showed loss of PTCH1 and expansion in the GLI1 region (Naylor et al. 2005) , immunohistological identification of SHH was higher in breast cancers (Cui et al. 2010) , Moreover, the Hh signaling pathway is activated in breast CSC (Tanaka et al. 2009) Hh signaling components are actually activated in advanced human colon cancer cells and their CSCs (Varnat et al. 2010) , GLI1 expression was increased in colon CSCs (Varnat et al. 2010) . Hence, metastatic colon cancers could conceivably be treated by blocking Hh signaling (Varnat et al. 2010) ensnared a vital role for Notch signaling in the selfrenewal and maintenance of CSCs (Purow et al. 2005 ). Notch1 and its ligands DLL1 and JAG1 are overexpressed in the primary gliomas and cell lines and are associated with high grade gliomas and medulloblastomas (Purow et al. 2005) . In medulloblastomas, upregulated levels of Notch2 and its downstream targets have been linked with poor survival (Purow et al. 2005) . Furthermore, Fan et al. (2006) demonstrated that Notch inhibition in medulloblastomas cells prompted differentiation and indicated a reduction in CD133 ? cell frequency and HES1 expression. In human glioma cell lines, down-regulation of Notch signaling components expanded apoptosis and diminished cell proliferation (Purow et al. 2005) , whereas activation of Notch expanded the formation of neurosphere colonies . Notch components have been discovered to be up-regulated in the CD133
? fraction (Ulasov et al. 2010) and Notch hindrance in cultured glioma CSCs retarded their proliferation in vitro (Fan et al. 2010 ). Down-regulation of Notch components additionally sensitized CSCs to radiation or chemotherapeutic therapies and weakened xenograft tumor formation .
In breast cancer, activation of Notch4 has been shown to be sufficient to impel mammary adenocarcinomas, while Notch1 activation was sufficient to change mouse mammary epithelial cells in vitro and quickened tumor growth in vivo, proposing an oncogenic role for Notch receptors in mammary tumor development (Dievart et al. 1999) . Expression of Notch signaling components is common in human breast cancers, with Notch activation reached about 50 % (Pece et al. 2004) , whereas high JAG1 and NOTCH1 expression is associated with poor survival (Reedijk et al. 2005) . Restraint of Notch1 and Notch4 signaling in both primary breast cancer samples and cell lines resulted in a decreased frequency of CD44 ? / CD24 low cells and a diminished capacity to form tumors in vivo (Harrison et al. 2010) , whereas inhibition of Notch4 had a more vigorous impact suggesting its involvement in CSC activity.
In colon cancer, it has been suggested that Notch signaling pathway plays a role in the initiation of colon malignancy but not in its progression. Supporting this idea is the finding that Notch signals are high in early colorectal cancers (Reedijk et al. 2008 ) and appear to be lower in the advanced cancers (Fre et al. 2005 ).
Notch signaling is active in human colon CSCs (Hoey et al. 2009) . In a xenograft model of OMP-C9 colon cancer cells, targeted inhibition of the Notch ligand DLL4 by utilizing an anti-DLL4 antibody hindered tumor development and lessened the expression of HES1, the proliferation of tumor cells and tumorigenicity, coinciding with lower frequency of CSCs (Hoey et al. 2009 ). Additionally. It was found that colon CSCs highly express Notch signaling factors and that Notch is essential for self-renewal and tumor initiation (Sikandar et al. 2010) . Components of the Notch signaling pathway, including Notch1, HES1 and JAG1, were highly expressed in colon CSCs, whereas high Notch activity was detected using a reporter assay. In these studies, blocking of Notch signaling with small molecule inhibitors or shRNAs down regulated HES1 expression and instigated cells to differentiate into MUC2
? cells. In summary, Notch signaling is likely to be essential for colon CSC proliferation, survival, and ensuing tumor formation.
Wnt pathway
Two pathways have been recognized for Wnt signaling: the canonical pathway where Wnt signaling happens through b-catenin and is included in cell fate determination; and the non-canonical pathway where Wnt signaling, by means of a b-catenin independent pathway, is involved in cell movement and polarity. While the latter has been indicated to be important in embryogenesis, little is known about its role in cancer stem cell biology (Trowbridge et al. 2006) .
In the breast cancer, Wnt signaling was first embroiled in mammary tumors when the mouse mammary tumor virus (MMTV) was found to coordinate into the Int-1 (Wnt1) locus, and overexpression of Wnt1 affected mammary tumorigenesis (Tsukamoto et al. 1988) . Various reports have recognized the dysregulation of the Wnt pathway in breast tumors (Zardawi et al. 2009 ). Down-regulation of the secreted Frizzled-related proteins (SFRPs), which are Wnt inhibitors, has been observed in breast cancers (Veeck et al. 2008) . In numerous cancers, mutations in the Wnt pathway are usually found, yet they are less common in breast cancer. Mutations within adenomatous polyposis coli (APC) have been described in 18 % of breast cancers, however mutations have not been recognized in CTNNB1 (the gene encoding bcatenin) (Geyer et al. 2011) . Studies in breast cancer cell lines have demonstrated that stem cell populations are more resistant to radiation therapy and that Wnt/bcatenin signaling intervenes resistance (Debeb et al. 2009 ). Recently Zhang et al. (2010) assessed radiation resistance in CSCs isolated from p53-null mouse mammary tumors. These CSCs populations had altered DNA repair because of radiation and increased AKT (a serine-threonine protein kinase) and b-catenin activation. By utilizing the inhibitor perifosine, they were able to block AKT and b-catenin activation and sensitize the cells to radiation.
In brain cancers, aberrant WNT signaling was first implicated in brain tumors through investigation of patients with Turcot's syndrome, which includes an APC mutation connected to a high frequency of colorectal cancers and brain tumors, especially medulloblastoma (Wechsler-Reya and Scott 2001). Mutations in APC, catenin, and Axin were likewise found in sporadic medulloblastomas (Baeza et al. 2003) . The Wnt antagonist DKK-1 has been ensnared as a medulloblastoma suppressor that is epigenetically silenced during tumorigenesis, and its re-actuation diminished tumor cell growth by 60 % while expanding apoptosis fourfold (Vibhakar et al. 2007 ). Altogether, it can be concluded that Wnt regulates selfrenewal in normal stem cells and is dysregulated in a group of patients with brain tumors. However, the role of Wnt in brain CSCs has not been widely considered.
In colorectal cancer, the majority of colorectal cancer (CRC) is associated with mutations in key components of the Wnt signaling pathway (Holcombe et al. 2002) . APC gene is a well-known tumor suppressor that assumes a focal role in the Wnt signaling pathway by targeting b-catenin for destruction. Dysregulated Wnt activation is likewise prominent around sporadic colon cancers. Inactivating mutations in APC are found in up to 80 % of sporadic colon cancers and activating mutations of b-catenin are additionally discovered, both of which culminate in heightened Wnt signaling (Pinto et al. 2003) . Studies concentrating on the Wnt pathway and its role in colon cancer stem cell function are limited. Nonetheless, Wnt activity has been implicated to plan an essential role inside the CD133
? population of colorectal malignancy. Evidence for Wnt activity within colon CSCs was additionally reported by Ernst et al. (2011) . It was found in this study that upon gene expression profiling of CD133
? versus CD133 -cells from primary patient samples, EGR1 (Early Growth Response Protein 1) demonstrated the highest expression within the CD133
? fraction. EGR1 enhances Wnt signaling through the up-regulation of TCF4, which induces the stem cell marker LGR5 (Ernst et al. 2011) (Fig. 1) .
Hedgehog (Hh) pathway
The Hh signaling pathway plays important roles in embryonic development. Distinctive parts of the embryo have diverse concentrations of Hh signaling proteins (Athar et al. 2006) . The Hh pathway assumes a fundamental role in the development of skin, sebaceous glands and hair follicles (Palma et al. 2005) as well as postnatal and adult brain development (Lum and Beachy 2004) . The pathway gets its name from its polypeptide ligand, an intercellular signaling molecule known as Hedgehog (Hh) found in fruit flies of the genus Drosophila (Athar et al. 2006) . Components of the mammalian Hh pathway includes the ligands Sonic (SHH), Desert (DHH) and Indian (IHH) Hh, the membrane receptor Patched (PTCH1/2), signal transducer Smoothened (SMO) and the G protein coupled receptor, and the downstream mediators of gene expression, the GLI zinc finger transcription factors (GLI1, GLI2 and GLI3) (Lum and Beachy 2004) . GLIs go about as repressors in the absence of Hh signaling. In the absence of the ligand, PTCH1 suppresses SMO and averts GLI modulation (Lum and Beachy 2004) .
Sonic Hedgehog (SHH) is one of the best studied pathways in CNS development and it is well known for its role in brain growth and patterning during development (Dessaud et al. 2008) . The distinguishing role of signaling pathways in medulloblastoma emerged from the discovery that patients with Gorlin syndrome have inactivating PTCH1 mutations, and that they have a higher inclination for developing medulloblastoma and skin basal cell carcinomas (Hahn et al. 1996) . In mouse models, changes in Ptch1 accelerate the advancement of medulloblastoma (Goodrich et al. 1997) . Furthermore, numerous sporadic human medulloblastoma harbors mutations in the Hh pathway (Manoranjan et al. 2012) . Bar et al. (2007) found that the transcription factor GLI1 is highly expressed in 26 % of primary glioblastoma multiforme (GBM), and 57 % of cell lines, and the ligand SHH is expressed in GBM-derived tumorspheres. Restraint of GLI1 with cyclopamine or GLI1 shRNA diminished glioma development in vitro as well as primary and secondary sphere formation, indicating the depletion of CSCs. ALDH1 activity and dye exclusion, which are connected with stem-like phenotypes, were also diminished upon restraining GLI1 with cyclopamine treatment. In concurrence with the studies demonstrating that CD133
? GBM stem-like cells are impervious to radiation therapy (Bao et al. 2006) , other studies indicated that combining cyclopamine with radiation treatment caused a reduction in growth rate in vitro (Clement et al. 2007) .
In breast cancers, comparative genomic hybridization analysis of human breast cancer specimens and cell lines uncovered a common loss in the chromosomal PTCH1 region (19 % of samples) and expansion in the GLI1 region (Naylor et al. 2005) . PTCH1 was likewise demonstrated to be silenced through promoter methylation (Wolf et al. 2007) . SMO is expressed at higher amounts in Ductal carcinoma in situ and invasive ductal carcinoma (IDC), where its constitutive activation in mouse mammary glands brings about ductal dysplasia (Moraes et al. 2009 ). Immunohistological identification of SHH was higher in breast cancers comparing with normal tissue (Cui et al. 2010) . Moreover, the Hh signaling pathway was discovered to be activated in the CSC-enriched CD44
? CD24 -/low population of breast cancer (Tanaka et al. 2009 ). The strongest confirmation for Hh involvement in breast carcinogenesis originates from a study in which restrictive over-expression of GLI1 alone in the mouse mammary gland was sufficient to impel tumor formation (Fiaschi et al. 2009 ). Altogether, these studies suggest that the Hh signaling pathway is fundamental for self-renewal and proliferation of breast CSCs. Further studies may need to explore the role of Hh in stem cell maintenance, epithelial-stromal interactions and EMT, to identify contributions by this pathway to the initiation and progression of breast cancer.
In colon cancers, Hh activation occurs by means of transcriptional up-regulation of the Hh ligands rather than mutation (Theunissen and de Sauvage 2009) . Increased transcript levels of SHH and its downstream target GLI2 are revealed in colon cancers (Douard et al. 2006 ). Expression of IHH, which is included in the differentiation of enterocytes, has been suggested to be lost in early phases of human colorectal carcinogenesis (van den Brink et al. 2004) . It is suggested, however, that Hh signaling increases with colon cancer progression (Yoshikawa et al. 2009 ). It was found further that Hh signaling components are actually activated in advanced human colon cancer cells and their CSCs, where GLI1 expression was higher in CD133 ? cells from patients with advance metastatic cancers (Varnat et al. 2010) . This study showed also that active Hh signaling is crucial for the survival and development of the CD133
? cells in vivo. Hence, metastatic colon cancers could conceivably be treated by blocking Hh signaling (Varnat et al. 2010 ).
Conclusion and perspectives
While there has been much debate encompassing the CSC hypothesis, it is clear that there is a subpopulation of cells in numerous tumors that share the molecular signatures with stem cells. Intriguingly, despite the possible biological heterogeneity of the distinctive histological origin of CSCs, they appear to be of low immunogenicity with immune suppressive activity comparing with non-CSC cancerous cells. This fits well with the assumed function credited to CSCs i.e. their capacity to survive in order to give rise to new, more differentiated cancerous cells that will permit the development and expansion of the tumor in the body.
While the Notch, Wnt and Hh pathways clearly play paramount roles in normal and CSCs, there are many additional pathways that likewise also participate in the maintenance of tissue homeostasis whose deregulation can prompt cancer growth. Thus if CSCs are to be targeted therapeutically, a combinational strategy has to be adopted to target multiple signaling pathways. On the other hand, the molecular identification of shared CSC antigens and elucidation of the mechanism of CSC to evade immune surveillance may inspire the development of immunotherapeutic strategies that are broadly effective against cancers, regardless of their origin.
In summary, intensive investigations on the part of developmental signaling pathways and immunobiological properties of CSCs introduce an opportunity for productive collaborations of multiple disciplines including developmental biology, immunology and oncology. Future researches are promised to develop novel therapeutic strategies to target CSCs, thus offering new modalities to end tumor development and eliminate recurrence.
